Publication Type:

Journal Article

Source:

International Journal of Pharma and Bio Sciences, Volume 4, Number 3, p.P890-P896 (2013)

URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84881281037&partnerID=40&md5=8e6d9cd3ab838c5e39b42d9bda75c035

Keywords:

acute hemorrhagic pancreatitis, add on therapy, adjuvant therapy, antibody production, antidiabetic activity, article, Blood pressure, cardiovascular risk, dipeptidyl peptidase IV inhibitor, drug accumulation, drug blood level, drug dose increase, drug effect, drug efficacy, drug half life, drug induced headache, drug safety, drug tolerability, drug withdrawal, exendin 4, gastrointestinal symptom, glimepiride, glitazone derivative, glucagon like peptide 1, glycemic control, hemoglobin A1c, hemorrhagic pancreatitis, human, impaired glucose tolerance, insulin dependent diabetes mellitus, insulin glargine, linagliptin, liraglutide, lixisenatide, metformin, nausea, non insulin dependent diabetes mellitus, nonhuman, obesity, oral antidiabetic agent, pancreas islet beta cell, placebo, saxagliptin, side effect, sitagliptin, sulfonylurea derivative, tetrahydrolipstatin, unspecified side effect, vildagliptin, vomiting, weight reduction

Abstract:

Glucagon-like peptide 1 (GLP-1) receptor agonists, are one among the latest addition of medication included for the management of type 2 diabetes. Liraglutide, a novel long acting glucagon-like peptide analogue, is effective at improving indices of glycemic control. It has good tolerability and safety profile. It acts in a glucose-dependent manner. In controlled trials, it was observed that it produce short-term glucose lowering effects, with the reduction of HbA1C of up to 1.3 % which is comparable with oral agents. The beneficial effects observed for liraglutide was on reduction of weight (1-3.4 kg) and blood pressure (2.1-6.7mmHg). The formation of antibodies against Liraglutide was comparatively less than that of exenatide. The effects of liraglutide on beta-cell function, cardiovascular risk and disease progression are anticipated from long-term clinical trials results. There are on-going or in development trials exploring the effects of liraglutide in prediabetes, obesity and type 1 diabetes.

Notes:

cited By (since 1996)1

Cite this Research Publication

B. T. Balagopal and Joseph, S., “Incretin analogue, liraglutide a newer treatment approach for type-2 diabetes mellitus”, International Journal of Pharma and Bio Sciences, vol. 4, pp. P890-P896, 2013.

207
PROGRAMS
OFFERED
5
AMRITA
CAMPUSES
15
CONSTITUENT
SCHOOLS
A
GRADE BY
NAAC, MHRD
9th
RANK(INDIA):
NIRF 2017
150+
INTERNATIONAL
PARTNERS